Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Cytotoxic Therapy

Tumour Site

Ovarian Cancer

Presenters

Hans Gelderblom

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

H. Gelderblom1, O. Saavedra Santa Gadea2, M. Jalving3, I. Desar4, J.A. Gietema3, A. Oberoi5, C. Van Herpen6, J.R. Kroep7, R. Frederiksen Franzen8, A. Bellon9, S. Micallef10, T. Tat11, V. Dozio11, N. Luong12, E. Rodrigo Imedio8

Author affiliations

  • 1 Medical Oncology Dept, Leiden University Medical Center, 2333 ZA - Leiden/NL
  • 2 Early Drug Development Unit (phase 1 Unit), Vall d'Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 3 Medical Oncology Department, UMCG - University Medical Center Groningen, 9700 RB - Groningen/NL
  • 4 Medical Oncology Dept., Radboud University Medical Center, Nijmegen, 6525 GA - Nijmegen/NL
  • 5 Medical Oncology Department, Vall d'Hebron Institute of Oncology - Cellex Center, 8035 - Barcelona/ES
  • 6 Medical Oncology Dept, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 7 Medical Oncology Department, LUMC-Leiden University Medical Center, 2333 ZA - Leiden/NL
  • 8 Oncology Global Clinical Development Department, Debiopharm International S.A., 1002 - Lausanne/CH
  • 9 Clinical Development Department, Debiopharm International S.A., 1002 - Lausanne/CH
  • 10 Biostatistics And Data Management, Debiopharm International S.A., 1002 - Lausanne/CH
  • 11 Oncology Global Clinical Development Department, Debiopharm International S.A., 1006 - Lausanne/CH
  • 12 Search And Evaluation Department, Debiopharm International S.A., 1002 - Lausanne/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 630P

Background

Cell cycle defects are common in cancer and cells rely on checkpoint proteins, such as WEE1, to avoid excess DNA damage. WEE1 inhibition abrogates S phase and G2-M checkpoints, leading to mitotic catastrophe and apoptosis. Debio 0123 is an oral, highly selective, brain-penetrant WEE1 inhibitor that has shown synergy with CP preclinically. Debio 0123-101 (NCT03968653) is a Phase 1 study evaluating Debio 0123 + CP. Arm A dose escalation (DE) data were reported at ASCO 2023; here, complete Debio 0123 DE and RP2D data are described.

Methods

Pts with advanced solid tumors recurring or progressing after platinum-based therapy were included. In Arm A, Debio 0123 was given as monotherapy in cycle (C) 1 (single dose on day [D] -3; qd over D1–3) and with CP from C2 (D1–3 q21d) until end of treatment (EOT). In Arm B, Debio 0123 was given with CP on D1–3 and D8–10, from C1 to EOT. CP AUC5 was given on D1 of each 21-day cycle in both arms.

Results

Data from both arms are reported. Overall, 55 pts (Arm A: 38; Arm B: 17) were treated (3 ongoing). Median pt age was 62 years, 82% were female, and median number of prior lines of systemic therapy was 3. The most common cancer was ovarian cancer (OC) (40%). Using a Bayesian logistic regression model-guided DE, Debio 0123 doses of 30–720 mg were tested. The maximum tolerated dose was declared at 520 mg (both arms). Based on overall safety, efficacy and PK/PD data, the RP2D was selected as 520 mg, with Arm B schedule. Overall, Debio 0123 was well-tolerated with manageable toxicity, in line with that expected for CP monotherapy. The most common related adverse events were thrombocytopenia, anaemia, fatigue, nausea, vomiting and QTc prolongation, mainly low grade. Of 48 evaluable pts, 7 had confirmed partial response (cPR) and 24 had stable disease (SD). Of 20 pts with OC, 6 had cPR and 11 had SD (one with 29% tumor shrinkage). Overall, median duration of response and progression-free survival were 8.5 (4.4–NR) and 5.5 months (3.4–6.6), respectively.

Conclusions

Debio 0123 + CP showed encouraging antitumor activity in heavily pretreated pts with solid tumors, with a manageable safety profile. An expansion cohort in platinum-resistant OC is ongoing.

Clinical trial identification

NCT03968653.

Editorial acknowledgement

Editorial assistance was provided by Dr Georgia Greaves of Cancer Communications and Consultancy Ltd (part of Bioscript Group).

Legal entity responsible for the study

Debiopharm International SA.

Funding

Debiopharm International SA.

Disclosure

H. Gelderblom: Financial Interests, Institutional, Local PI: Daiichi, Deciphera, Novartis, Cytovation; Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim, AmMax Bio, Debiopharm, Abbisko. M. Jalving: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: Merck, Pierre Fabre. J.A. Gietema: Financial Interests, Institutional, Research grant paid to the institution UMCG: Roche, Siemens, AbbVie. R. Frederiksen Franzen: Financial Interests, Personal, Full or part-time Employment: Debiopharm International SA. S. Micallef, V. Dozio, A. Bellon, N. Luong: Financial Interests, Institutional, Full or part-time Employment: Debiopharm International S.A. T. Tat: Financial Interests, Institutional, Full or part-time Employment, Employed as statistician: Debiopharm. E. Rodrigo Imedio: Financial Interests, Personal, Full or part-time Employment: Debiopharm International; Non-Financial Interests, Other, Full time employee: Debiopharm International; Non-Financial Interests, Member: SEOM, ASCO. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.